Atopic Dermatitis With a Focus on Moderate to Severe Disease
Atopic dermatitis (AD) affects nearly 10% of children and 7% of adults in the United States. Initial treatments for all patients with AD include vigilant skin hygiene and moisturizers. Other treatments, depending on disease severity, include topical corticosteroids, calcineurin inhibitors, or photot...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Aldredge, Lakshi M. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2020transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
6 |
|---|
| Übergeordnetes Werk: |
Enthalten in: The Use of Solicited Publishing by Academic Surgeons - Nguyen, Vi ELSEVIER, 2018, JNP : official journal of the American College of Nurse Practitioner, New York, NY [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:16 ; year:2020 ; number:10 ; pages:726-731 ; extent:6 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.nurpra.2020.08.026 |
|---|
| Katalog-ID: |
ELV05209958X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV05209958X | ||
| 003 | DE-627 | ||
| 005 | 20230626032835.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210910s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.nurpra.2020.08.026 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001208.pica |
| 035 | |a (DE-627)ELV05209958X | ||
| 035 | |a (ELSEVIER)S1555-4155(20)30472-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.65 |2 bkl | ||
| 100 | 1 | |a Aldredge, Lakshi M. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Atopic Dermatitis With a Focus on Moderate to Severe Disease |
| 264 | 1 | |c 2020transfer abstract | |
| 300 | |a 6 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Atopic dermatitis (AD) affects nearly 10% of children and 7% of adults in the United States. Initial treatments for all patients with AD include vigilant skin hygiene and moisturizers. Other treatments, depending on disease severity, include topical corticosteroids, calcineurin inhibitors, or phototherapy as maintenance therapy to lengthen the time to relapse. Systemic immunosuppressants are recommended when these regimens are inadequate but are associated with poor side effect profiles. Recent discoveries are leading to more effective and safer immunomodulatory therapies. An overview of AD clinical pathways will focus on moderate to severe disease, including a discussion of the newest available treatment—dupilumab. | ||
| 520 | |a Atopic dermatitis (AD) affects nearly 10% of children and 7% of adults in the United States. Initial treatments for all patients with AD include vigilant skin hygiene and moisturizers. Other treatments, depending on disease severity, include topical corticosteroids, calcineurin inhibitors, or phototherapy as maintenance therapy to lengthen the time to relapse. Systemic immunosuppressants are recommended when these regimens are inadequate but are associated with poor side effect profiles. Recent discoveries are leading to more effective and safer immunomodulatory therapies. An overview of AD clinical pathways will focus on moderate to severe disease, including a discussion of the newest available treatment—dupilumab. | ||
| 650 | 7 | |a diagnostic criteria |2 Elsevier | |
| 650 | 7 | |a atopic dermatitis |2 Elsevier | |
| 650 | 7 | |a crisaborole |2 Elsevier | |
| 650 | 7 | |a step care management |2 Elsevier | |
| 650 | 7 | |a dupilumab |2 Elsevier | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |a Nguyen, Vi ELSEVIER |t The Use of Solicited Publishing by Academic Surgeons |d 2018 |d JNP : official journal of the American College of Nurse Practitioner |g New York, NY [u.a.] |w (DE-627)ELV000088234 |
| 773 | 1 | 8 | |g volume:16 |g year:2020 |g number:10 |g pages:726-731 |g extent:6 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.nurpra.2020.08.026 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.65 |j Chirurgie |q VZ |
| 951 | |a AR | ||
| 952 | |d 16 |j 2020 |e 10 |h 726-731 |g 6 | ||
| author_variant |
l m a lm lma |
|---|---|
| matchkey_str |
aldredgelakshim:2020----:tpcemttsihfcsnoeae |
| hierarchy_sort_str |
2020transfer abstract |
| bklnumber |
44.65 |
| publishDate |
2020 |
| allfields |
10.1016/j.nurpra.2020.08.026 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001208.pica (DE-627)ELV05209958X (ELSEVIER)S1555-4155(20)30472-4 DE-627 ger DE-627 rakwb eng 610 VZ 44.65 bkl Aldredge, Lakshi M. verfasserin aut Atopic Dermatitis With a Focus on Moderate to Severe Disease 2020transfer abstract 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Atopic dermatitis (AD) affects nearly 10% of children and 7% of adults in the United States. Initial treatments for all patients with AD include vigilant skin hygiene and moisturizers. Other treatments, depending on disease severity, include topical corticosteroids, calcineurin inhibitors, or phototherapy as maintenance therapy to lengthen the time to relapse. Systemic immunosuppressants are recommended when these regimens are inadequate but are associated with poor side effect profiles. Recent discoveries are leading to more effective and safer immunomodulatory therapies. An overview of AD clinical pathways will focus on moderate to severe disease, including a discussion of the newest available treatment—dupilumab. Atopic dermatitis (AD) affects nearly 10% of children and 7% of adults in the United States. Initial treatments for all patients with AD include vigilant skin hygiene and moisturizers. Other treatments, depending on disease severity, include topical corticosteroids, calcineurin inhibitors, or phototherapy as maintenance therapy to lengthen the time to relapse. Systemic immunosuppressants are recommended when these regimens are inadequate but are associated with poor side effect profiles. Recent discoveries are leading to more effective and safer immunomodulatory therapies. An overview of AD clinical pathways will focus on moderate to severe disease, including a discussion of the newest available treatment—dupilumab. diagnostic criteria Elsevier atopic dermatitis Elsevier crisaborole Elsevier step care management Elsevier dupilumab Elsevier Enthalten in Elsevier Nguyen, Vi ELSEVIER The Use of Solicited Publishing by Academic Surgeons 2018 JNP : official journal of the American College of Nurse Practitioner New York, NY [u.a.] (DE-627)ELV000088234 volume:16 year:2020 number:10 pages:726-731 extent:6 https://doi.org/10.1016/j.nurpra.2020.08.026 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.65 Chirurgie VZ AR 16 2020 10 726-731 6 |
| spelling |
10.1016/j.nurpra.2020.08.026 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001208.pica (DE-627)ELV05209958X (ELSEVIER)S1555-4155(20)30472-4 DE-627 ger DE-627 rakwb eng 610 VZ 44.65 bkl Aldredge, Lakshi M. verfasserin aut Atopic Dermatitis With a Focus on Moderate to Severe Disease 2020transfer abstract 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Atopic dermatitis (AD) affects nearly 10% of children and 7% of adults in the United States. Initial treatments for all patients with AD include vigilant skin hygiene and moisturizers. Other treatments, depending on disease severity, include topical corticosteroids, calcineurin inhibitors, or phototherapy as maintenance therapy to lengthen the time to relapse. Systemic immunosuppressants are recommended when these regimens are inadequate but are associated with poor side effect profiles. Recent discoveries are leading to more effective and safer immunomodulatory therapies. An overview of AD clinical pathways will focus on moderate to severe disease, including a discussion of the newest available treatment—dupilumab. Atopic dermatitis (AD) affects nearly 10% of children and 7% of adults in the United States. Initial treatments for all patients with AD include vigilant skin hygiene and moisturizers. Other treatments, depending on disease severity, include topical corticosteroids, calcineurin inhibitors, or phototherapy as maintenance therapy to lengthen the time to relapse. Systemic immunosuppressants are recommended when these regimens are inadequate but are associated with poor side effect profiles. Recent discoveries are leading to more effective and safer immunomodulatory therapies. An overview of AD clinical pathways will focus on moderate to severe disease, including a discussion of the newest available treatment—dupilumab. diagnostic criteria Elsevier atopic dermatitis Elsevier crisaborole Elsevier step care management Elsevier dupilumab Elsevier Enthalten in Elsevier Nguyen, Vi ELSEVIER The Use of Solicited Publishing by Academic Surgeons 2018 JNP : official journal of the American College of Nurse Practitioner New York, NY [u.a.] (DE-627)ELV000088234 volume:16 year:2020 number:10 pages:726-731 extent:6 https://doi.org/10.1016/j.nurpra.2020.08.026 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.65 Chirurgie VZ AR 16 2020 10 726-731 6 |
| allfields_unstemmed |
10.1016/j.nurpra.2020.08.026 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001208.pica (DE-627)ELV05209958X (ELSEVIER)S1555-4155(20)30472-4 DE-627 ger DE-627 rakwb eng 610 VZ 44.65 bkl Aldredge, Lakshi M. verfasserin aut Atopic Dermatitis With a Focus on Moderate to Severe Disease 2020transfer abstract 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Atopic dermatitis (AD) affects nearly 10% of children and 7% of adults in the United States. Initial treatments for all patients with AD include vigilant skin hygiene and moisturizers. Other treatments, depending on disease severity, include topical corticosteroids, calcineurin inhibitors, or phototherapy as maintenance therapy to lengthen the time to relapse. Systemic immunosuppressants are recommended when these regimens are inadequate but are associated with poor side effect profiles. Recent discoveries are leading to more effective and safer immunomodulatory therapies. An overview of AD clinical pathways will focus on moderate to severe disease, including a discussion of the newest available treatment—dupilumab. Atopic dermatitis (AD) affects nearly 10% of children and 7% of adults in the United States. Initial treatments for all patients with AD include vigilant skin hygiene and moisturizers. Other treatments, depending on disease severity, include topical corticosteroids, calcineurin inhibitors, or phototherapy as maintenance therapy to lengthen the time to relapse. Systemic immunosuppressants are recommended when these regimens are inadequate but are associated with poor side effect profiles. Recent discoveries are leading to more effective and safer immunomodulatory therapies. An overview of AD clinical pathways will focus on moderate to severe disease, including a discussion of the newest available treatment—dupilumab. diagnostic criteria Elsevier atopic dermatitis Elsevier crisaborole Elsevier step care management Elsevier dupilumab Elsevier Enthalten in Elsevier Nguyen, Vi ELSEVIER The Use of Solicited Publishing by Academic Surgeons 2018 JNP : official journal of the American College of Nurse Practitioner New York, NY [u.a.] (DE-627)ELV000088234 volume:16 year:2020 number:10 pages:726-731 extent:6 https://doi.org/10.1016/j.nurpra.2020.08.026 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.65 Chirurgie VZ AR 16 2020 10 726-731 6 |
| allfieldsGer |
10.1016/j.nurpra.2020.08.026 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001208.pica (DE-627)ELV05209958X (ELSEVIER)S1555-4155(20)30472-4 DE-627 ger DE-627 rakwb eng 610 VZ 44.65 bkl Aldredge, Lakshi M. verfasserin aut Atopic Dermatitis With a Focus on Moderate to Severe Disease 2020transfer abstract 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Atopic dermatitis (AD) affects nearly 10% of children and 7% of adults in the United States. Initial treatments for all patients with AD include vigilant skin hygiene and moisturizers. Other treatments, depending on disease severity, include topical corticosteroids, calcineurin inhibitors, or phototherapy as maintenance therapy to lengthen the time to relapse. Systemic immunosuppressants are recommended when these regimens are inadequate but are associated with poor side effect profiles. Recent discoveries are leading to more effective and safer immunomodulatory therapies. An overview of AD clinical pathways will focus on moderate to severe disease, including a discussion of the newest available treatment—dupilumab. Atopic dermatitis (AD) affects nearly 10% of children and 7% of adults in the United States. Initial treatments for all patients with AD include vigilant skin hygiene and moisturizers. Other treatments, depending on disease severity, include topical corticosteroids, calcineurin inhibitors, or phototherapy as maintenance therapy to lengthen the time to relapse. Systemic immunosuppressants are recommended when these regimens are inadequate but are associated with poor side effect profiles. Recent discoveries are leading to more effective and safer immunomodulatory therapies. An overview of AD clinical pathways will focus on moderate to severe disease, including a discussion of the newest available treatment—dupilumab. diagnostic criteria Elsevier atopic dermatitis Elsevier crisaborole Elsevier step care management Elsevier dupilumab Elsevier Enthalten in Elsevier Nguyen, Vi ELSEVIER The Use of Solicited Publishing by Academic Surgeons 2018 JNP : official journal of the American College of Nurse Practitioner New York, NY [u.a.] (DE-627)ELV000088234 volume:16 year:2020 number:10 pages:726-731 extent:6 https://doi.org/10.1016/j.nurpra.2020.08.026 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.65 Chirurgie VZ AR 16 2020 10 726-731 6 |
| allfieldsSound |
10.1016/j.nurpra.2020.08.026 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001208.pica (DE-627)ELV05209958X (ELSEVIER)S1555-4155(20)30472-4 DE-627 ger DE-627 rakwb eng 610 VZ 44.65 bkl Aldredge, Lakshi M. verfasserin aut Atopic Dermatitis With a Focus on Moderate to Severe Disease 2020transfer abstract 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Atopic dermatitis (AD) affects nearly 10% of children and 7% of adults in the United States. Initial treatments for all patients with AD include vigilant skin hygiene and moisturizers. Other treatments, depending on disease severity, include topical corticosteroids, calcineurin inhibitors, or phototherapy as maintenance therapy to lengthen the time to relapse. Systemic immunosuppressants are recommended when these regimens are inadequate but are associated with poor side effect profiles. Recent discoveries are leading to more effective and safer immunomodulatory therapies. An overview of AD clinical pathways will focus on moderate to severe disease, including a discussion of the newest available treatment—dupilumab. Atopic dermatitis (AD) affects nearly 10% of children and 7% of adults in the United States. Initial treatments for all patients with AD include vigilant skin hygiene and moisturizers. Other treatments, depending on disease severity, include topical corticosteroids, calcineurin inhibitors, or phototherapy as maintenance therapy to lengthen the time to relapse. Systemic immunosuppressants are recommended when these regimens are inadequate but are associated with poor side effect profiles. Recent discoveries are leading to more effective and safer immunomodulatory therapies. An overview of AD clinical pathways will focus on moderate to severe disease, including a discussion of the newest available treatment—dupilumab. diagnostic criteria Elsevier atopic dermatitis Elsevier crisaborole Elsevier step care management Elsevier dupilumab Elsevier Enthalten in Elsevier Nguyen, Vi ELSEVIER The Use of Solicited Publishing by Academic Surgeons 2018 JNP : official journal of the American College of Nurse Practitioner New York, NY [u.a.] (DE-627)ELV000088234 volume:16 year:2020 number:10 pages:726-731 extent:6 https://doi.org/10.1016/j.nurpra.2020.08.026 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.65 Chirurgie VZ AR 16 2020 10 726-731 6 |
| language |
English |
| source |
Enthalten in The Use of Solicited Publishing by Academic Surgeons New York, NY [u.a.] volume:16 year:2020 number:10 pages:726-731 extent:6 |
| sourceStr |
Enthalten in The Use of Solicited Publishing by Academic Surgeons New York, NY [u.a.] volume:16 year:2020 number:10 pages:726-731 extent:6 |
| format_phy_str_mv |
Article |
| bklname |
Chirurgie |
| institution |
findex.gbv.de |
| topic_facet |
diagnostic criteria atopic dermatitis crisaborole step care management dupilumab |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
The Use of Solicited Publishing by Academic Surgeons |
| authorswithroles_txt_mv |
Aldredge, Lakshi M. @@aut@@ |
| publishDateDaySort_date |
2020-01-01T00:00:00Z |
| hierarchy_top_id |
ELV000088234 |
| dewey-sort |
3610 |
| id |
ELV05209958X |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV05209958X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626032835.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">210910s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.nurpra.2020.08.026</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001208.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV05209958X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1555-4155(20)30472-4</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.65</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Aldredge, Lakshi M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Atopic Dermatitis With a Focus on Moderate to Severe Disease</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">6</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Atopic dermatitis (AD) affects nearly 10% of children and 7% of adults in the United States. Initial treatments for all patients with AD include vigilant skin hygiene and moisturizers. Other treatments, depending on disease severity, include topical corticosteroids, calcineurin inhibitors, or phototherapy as maintenance therapy to lengthen the time to relapse. Systemic immunosuppressants are recommended when these regimens are inadequate but are associated with poor side effect profiles. Recent discoveries are leading to more effective and safer immunomodulatory therapies. An overview of AD clinical pathways will focus on moderate to severe disease, including a discussion of the newest available treatment—dupilumab.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Atopic dermatitis (AD) affects nearly 10% of children and 7% of adults in the United States. Initial treatments for all patients with AD include vigilant skin hygiene and moisturizers. Other treatments, depending on disease severity, include topical corticosteroids, calcineurin inhibitors, or phototherapy as maintenance therapy to lengthen the time to relapse. Systemic immunosuppressants are recommended when these regimens are inadequate but are associated with poor side effect profiles. Recent discoveries are leading to more effective and safer immunomodulatory therapies. An overview of AD clinical pathways will focus on moderate to severe disease, including a discussion of the newest available treatment—dupilumab.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">diagnostic criteria</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">atopic dermatitis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">crisaborole</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">step care management</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">dupilumab</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Nguyen, Vi ELSEVIER</subfield><subfield code="t">The Use of Solicited Publishing by Academic Surgeons</subfield><subfield code="d">2018</subfield><subfield code="d">JNP : official journal of the American College of Nurse Practitioner</subfield><subfield code="g">New York, NY [u.a.]</subfield><subfield code="w">(DE-627)ELV000088234</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:16</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:10</subfield><subfield code="g">pages:726-731</subfield><subfield code="g">extent:6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.nurpra.2020.08.026</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.65</subfield><subfield code="j">Chirurgie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">16</subfield><subfield code="j">2020</subfield><subfield code="e">10</subfield><subfield code="h">726-731</subfield><subfield code="g">6</subfield></datafield></record></collection>
|
| author |
Aldredge, Lakshi M. |
| spellingShingle |
Aldredge, Lakshi M. ddc 610 bkl 44.65 Elsevier diagnostic criteria Elsevier atopic dermatitis Elsevier crisaborole Elsevier step care management Elsevier dupilumab Atopic Dermatitis With a Focus on Moderate to Severe Disease |
| authorStr |
Aldredge, Lakshi M. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV000088234 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 VZ 44.65 bkl Atopic Dermatitis With a Focus on Moderate to Severe Disease diagnostic criteria Elsevier atopic dermatitis Elsevier crisaborole Elsevier step care management Elsevier dupilumab Elsevier |
| topic |
ddc 610 bkl 44.65 Elsevier diagnostic criteria Elsevier atopic dermatitis Elsevier crisaborole Elsevier step care management Elsevier dupilumab |
| topic_unstemmed |
ddc 610 bkl 44.65 Elsevier diagnostic criteria Elsevier atopic dermatitis Elsevier crisaborole Elsevier step care management Elsevier dupilumab |
| topic_browse |
ddc 610 bkl 44.65 Elsevier diagnostic criteria Elsevier atopic dermatitis Elsevier crisaborole Elsevier step care management Elsevier dupilumab |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| hierarchy_parent_title |
The Use of Solicited Publishing by Academic Surgeons |
| hierarchy_parent_id |
ELV000088234 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
The Use of Solicited Publishing by Academic Surgeons |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV000088234 |
| title |
Atopic Dermatitis With a Focus on Moderate to Severe Disease |
| ctrlnum |
(DE-627)ELV05209958X (ELSEVIER)S1555-4155(20)30472-4 |
| title_full |
Atopic Dermatitis With a Focus on Moderate to Severe Disease |
| author_sort |
Aldredge, Lakshi M. |
| journal |
The Use of Solicited Publishing by Academic Surgeons |
| journalStr |
The Use of Solicited Publishing by Academic Surgeons |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2020 |
| contenttype_str_mv |
zzz |
| container_start_page |
726 |
| author_browse |
Aldredge, Lakshi M. |
| container_volume |
16 |
| physical |
6 |
| class |
610 VZ 44.65 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Aldredge, Lakshi M. |
| doi_str_mv |
10.1016/j.nurpra.2020.08.026 |
| dewey-full |
610 |
| title_sort |
atopic dermatitis with a focus on moderate to severe disease |
| title_auth |
Atopic Dermatitis With a Focus on Moderate to Severe Disease |
| abstract |
Atopic dermatitis (AD) affects nearly 10% of children and 7% of adults in the United States. Initial treatments for all patients with AD include vigilant skin hygiene and moisturizers. Other treatments, depending on disease severity, include topical corticosteroids, calcineurin inhibitors, or phototherapy as maintenance therapy to lengthen the time to relapse. Systemic immunosuppressants are recommended when these regimens are inadequate but are associated with poor side effect profiles. Recent discoveries are leading to more effective and safer immunomodulatory therapies. An overview of AD clinical pathways will focus on moderate to severe disease, including a discussion of the newest available treatment—dupilumab. |
| abstractGer |
Atopic dermatitis (AD) affects nearly 10% of children and 7% of adults in the United States. Initial treatments for all patients with AD include vigilant skin hygiene and moisturizers. Other treatments, depending on disease severity, include topical corticosteroids, calcineurin inhibitors, or phototherapy as maintenance therapy to lengthen the time to relapse. Systemic immunosuppressants are recommended when these regimens are inadequate but are associated with poor side effect profiles. Recent discoveries are leading to more effective and safer immunomodulatory therapies. An overview of AD clinical pathways will focus on moderate to severe disease, including a discussion of the newest available treatment—dupilumab. |
| abstract_unstemmed |
Atopic dermatitis (AD) affects nearly 10% of children and 7% of adults in the United States. Initial treatments for all patients with AD include vigilant skin hygiene and moisturizers. Other treatments, depending on disease severity, include topical corticosteroids, calcineurin inhibitors, or phototherapy as maintenance therapy to lengthen the time to relapse. Systemic immunosuppressants are recommended when these regimens are inadequate but are associated with poor side effect profiles. Recent discoveries are leading to more effective and safer immunomodulatory therapies. An overview of AD clinical pathways will focus on moderate to severe disease, including a discussion of the newest available treatment—dupilumab. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| container_issue |
10 |
| title_short |
Atopic Dermatitis With a Focus on Moderate to Severe Disease |
| url |
https://doi.org/10.1016/j.nurpra.2020.08.026 |
| remote_bool |
true |
| ppnlink |
ELV000088234 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1016/j.nurpra.2020.08.026 |
| up_date |
2024-07-06T22:05:54.389Z |
| _version_ |
1803869019848048640 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV05209958X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626032835.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">210910s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.nurpra.2020.08.026</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001208.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV05209958X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1555-4155(20)30472-4</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.65</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Aldredge, Lakshi M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Atopic Dermatitis With a Focus on Moderate to Severe Disease</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">6</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Atopic dermatitis (AD) affects nearly 10% of children and 7% of adults in the United States. Initial treatments for all patients with AD include vigilant skin hygiene and moisturizers. Other treatments, depending on disease severity, include topical corticosteroids, calcineurin inhibitors, or phototherapy as maintenance therapy to lengthen the time to relapse. Systemic immunosuppressants are recommended when these regimens are inadequate but are associated with poor side effect profiles. Recent discoveries are leading to more effective and safer immunomodulatory therapies. An overview of AD clinical pathways will focus on moderate to severe disease, including a discussion of the newest available treatment—dupilumab.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Atopic dermatitis (AD) affects nearly 10% of children and 7% of adults in the United States. Initial treatments for all patients with AD include vigilant skin hygiene and moisturizers. Other treatments, depending on disease severity, include topical corticosteroids, calcineurin inhibitors, or phototherapy as maintenance therapy to lengthen the time to relapse. Systemic immunosuppressants are recommended when these regimens are inadequate but are associated with poor side effect profiles. Recent discoveries are leading to more effective and safer immunomodulatory therapies. An overview of AD clinical pathways will focus on moderate to severe disease, including a discussion of the newest available treatment—dupilumab.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">diagnostic criteria</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">atopic dermatitis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">crisaborole</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">step care management</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">dupilumab</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Nguyen, Vi ELSEVIER</subfield><subfield code="t">The Use of Solicited Publishing by Academic Surgeons</subfield><subfield code="d">2018</subfield><subfield code="d">JNP : official journal of the American College of Nurse Practitioner</subfield><subfield code="g">New York, NY [u.a.]</subfield><subfield code="w">(DE-627)ELV000088234</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:16</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:10</subfield><subfield code="g">pages:726-731</subfield><subfield code="g">extent:6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.nurpra.2020.08.026</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.65</subfield><subfield code="j">Chirurgie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">16</subfield><subfield code="j">2020</subfield><subfield code="e">10</subfield><subfield code="h">726-731</subfield><subfield code="g">6</subfield></datafield></record></collection>
|
| score |
7.399063 |